NIH-Funded Study Identifies Potential New Stroke Treatment

Follow Drugslib on

March 17, 2025 -- In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The findings suggest that the treatment may work as an add-on therapy to standard stroke treatments in humans. The study was funded by the National Institutes of Health (NIH) and published in Stroke.

Led by Enrique Leira, M.D., and Anil Chauhan, Ph.D., at the University of Iowa, Iowa City, researchers used a well-established rodent model of stroke that closely simulates stroke in humans. They administered intravenous uric acid or saline control and monitored animals’ recovery over one month. Behavioral and neurological assessments, including MRI scans, were used to evaluate the treatment’s effects.

Mice treated with uric acid had better sensorimotor function—the primary outcome measure—30 days after stroke. More animals in the uric acid group also survived their stroke compared to control animals. However, some secondary outcome measures, such as brain damage, were not reduced.

The research teams used equal numbers of male and female animals and studied older, young, and obese mice, as well as rats with hypertension. Uric acid was efficacious across all groups, suggesting that the treatment could potentially perform well in human trials, including in people with stroke comorbidities.

Ischemic stroke, a leading cause of disability and death in the United States, occurs when a blood clot or other blockage in an artery cuts off blood supply to the brain. Strokes are treated with medications or surgery aimed to break up clots and restore blood flow to affected brain areas. These therapies are highly effective, but not all people fully recover. Using additional treatments that protect brain tissue from damage, either immediately before or during clot removal, could boost the effects of standard treatments and greatly improve recovery in patients.

The study was part of the NIH’s Stroke Preclinical Assessment Network (SPAN), a rigorous, transparent approach to preclinical research that mimics clinical trials. SPAN applies standard clinical practices, like randomization and blinded analysis, to animal studies, with the goal of finding agents that are likely to succeed in clinical trials. Recently, the network tested six promising stroke treatments and found one, uric acid, that showed efficacy. The current study described the results of this trial.

The study was supported by the National Institute of Neurological Disorders and Stroke (NINDS) (U01NS113388, U24NS113452) and the National Heart Lung and Blood Institute (R35HL139926).

Who

Walter Koroshetz, M.D., director, NINDS; and Francesca Bosetti, Ph.D. program director, NINDS, are available for interviews. To arrange an interview, please contact: [email protected].

Article

Patel, R.B., and Kumskova, M., et al. “Uric acid stroke cerebroprotection transcended sex, age, and comorbidities in a multicenter preclinical trial.” Stroke. March 17, 2025. DOI: 10.1161/STROKEAHA.124.048748.

About the National Institute of Neurological Disorders and Stroke (NINDS): NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Source: NIH

Posted : 2025-03-18 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords